|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 1.99B 1.74B 1.61B 1.49B 2.81B 190B 2.86B 19.24B 7.55B 93.39B 7.46B 7.3B 323B | P/E 2026 * |
5.38x | P/E 2027 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.49B 1.3B 1.21B 1.11B 2.1B 142B 2.14B 14.38B 5.64B 69.83B 5.58B 5.46B 241B | EV / Sales 2026 * |
0.81x | EV / Sales 2027 * | 0.76x |
| Free-Float |
95.19% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sarepta Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 63 | 26/06/2017 |
Ryan Wong
DFI | Director of Finance/CFO | 47 | 16/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 50 | 14/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 73 | 16/04/2015 |
| Director/Board Member | 87 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 67 | 02/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.77% | -1.42% | +12.57% | -24.79% | 3.26B | |
| -2.86% | -2.03% | -12.76% | -16.42% | 310M | |
| -4.05% | -4.82% | -47.57% | - | 50.76M | |
| Average | -2.89% | -2.60% | -15.92% | -20.61% | 1.21B | |
| Weighted average by Cap. | -1.90% | -1.51% | +9.56% | -24.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.84B 1.61B 1.49B 1.37B 2.6B 176B 2.65B 17.8B 6.98B 86.41B 6.9B 6.75B 298B | 1.42B 1.25B 1.16B 1.06B 2.01B 136B 2.05B 13.79B 5.41B 66.93B 5.35B 5.23B 231B |
| Net income | 413M 363M 336M 309M 584M 39.57B 596M 4B 1.57B 19.43B 1.55B 1.52B 67.1B | 87.36M 76.63M 70.97M 65.3M 124M 8.36B 126M 846M 332M 4.11B 328M 321M 14.18B |
| Net Debt | -501M -440M -407M -375M -709M -47.98B -723M -4.85B -1.9B -23.56B -1.88B -1.84B -81.37B | -902M -791M -732M -674M -1.27B -86.29B -1.3B -8.73B -3.42B -42.38B -3.39B -3.31B -146B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
